MA-BENU-NETWORKS
13.8.2019 13:37:10 CEST | Business Wire | Press release
Benu Networks , the leading software and solutions provider simplifying the industry’s most complex edge networks, announced the launch of its new virtual broadband network gateway (vBNG ). This new network function builds upon Benu Networks’ Software-Defined Edge (SD-Edge) Platform, which features a set of rich, virtualized functionalities that enable service providers to instantly cloudify their network, rapidly create and deliver new services, and easily scale network performance.
Modern consumer expectation and demand, particularly from the lens of a managed service provider, is constantly shifting. Buying behavior and criteria have drastically changed - gone are the days when triple play deals created great value to consumers and helped drive ARPU growth for service providers. Nowadays, residential subscribers are moving to single play broadband access, which adds pressure for managed service providers to create customized, cutting-edge offerings that continue to impress consumers. However, this level of agility has proved difficult to achieve for most MSPs, who still depend on hardware to manage subscriber sessions, authentication, and more. Plus, the need to reduce operational and capital expenses in the midst of margin erosion adds an additional layer of complexity for MSPs to manage.
“Our network has relied on Benu Networks’ software for 4 years, on dedicated appliances. We’re thrilled to see the addition of a vBNG to their platform,” said Khetan Gajjar, CTO of VAST Networks. “One of the key challenges we face, particularly as Africa’s leading Wi-Fi provider of services, is our ability to be agile and dynamic with the services we offer and scaling these efficiently while retaining our standard of performance. We currently do this with the SD-Edge Platform to millions of users. Now, with the Benu vBNG, we won’t have to think too hard about the scaling required to tailor services to each customer and building out new offerings and scaling to tens and hundreds of millions of users. A vBNG also allows us to deliver network scale much closer to the edge and allows us to expand into markets much more cost-effectively.”
The vBNG, running on the Benu SD-Edge Platform, helps service providers achieve this vision by streamlining packet processing as well as separating the control plane and data plane for dynamic scaling, added agility, optimal network performance, and cost reduction. The flexible, open architecture supports 3rd party service stitching on top of the breadth of functionality native to the vBNG. Service providers can now consolidate functions such as TDF/DPI, CGNAT, SG, and BNG, into a single virtualized platform for ultra-low latency and high performance. With the Benu Networks vBNG, service providers can go beyond just providing a ‘dumb pipe’ broadband connection and instead rapidly provision value-added services that reduce churn and increase ARPU.
“Releasing our vBNG as a part of the Benu SD-Edge Platform furthers our mission to simplify edge applications, “ said Mads Lillelund, CEO of Benu Networks. “We’re looking to drastically simplify network transformation and make it easy for service providers to be more agile and innovative without locking them into one vendor. With our vBNG, we’ve taken a massive step toward achieving this goal.”
The vBNG virtualizes integral network functionality, empowering service providers to seamlessly transition to a cloud-based 5G ready network. Benu Networks’ technology simplifies the complexity of network optimization, helping service providers rapidly scale their offerings, manage their network, and ensure the service experience. By disaggregating legacy network structures and eliminating hardware dependencies, service providers are free to move towards a modern network, reduce costs, and improve customer experience.
To schedule a demo, visit https://benunetworks.com/contact-us/ .
About Benu Networks:
Benu Networks is a leading software and solutions provider, simplifying the industry’s most complex edge networks. With a comprehensive set of products and innovative solutions coupled with over a decade in the industry, Benu Networks delivers solutions to instantly transform legacy access networks, elastically manage services, and carve the path to 5G. For more information, please visit the Benu Networks’ website: www.benunetworks.com . Follow us on Twitter @benunets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190813005390/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
